Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries

ACS Medicinal Chemistry Letters

Volumn 6, Issue 3, 2015, Pages 349-354

  Liu, Yi Liang ^a   Cao, Rong ^a   Wang, Yang ^a   Oldfield, Eric ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

diamidine; Farnesyl diphosphate synthase; inhibitor; T. brucei

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; FARNESYL DIPHOSPHATE SYNTHASE INHIBITOR; GERANYLTRANSFERASE; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITOR INTERACTION; IC50; LIGAND BINDING; LIPOPHILICITY; PRIORITY JOURNAL; TRYPANOSOMA BRUCEI; X RAY CRYSTALLOGRAPHY;

TRYPANOSOMA BRUCEI;

EID: 84924717794     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500528x     Document Type: Article

References (27)

1. Russell, R. G. Bisphosphonates: the first 40 years Bone 2011, 49, 2-19
2. Martin, M. B.; Arnold, W.; Heath, H. T., 3rd; Urbina, J. A.; Oldfield, E. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis Biochem. Biophys. Res. Commun. 1999, 263, 754-758
3. Bergstrom, J. D.; Bostedor, R. G.; Masarachia, P. J.; Reszka, A. A.; Rodan, G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase Arch. Biochem. Biophys. 2000, 373, 231-241
4. Boissier, S.; Ferreras, M.; Peyruchaud, O.; Magnetto, S.; Ebetino, F. H.; Colombel, M.; Delmas, P.; Delaisse, J. M.; Clezardin, P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases Cancer Res. 2000, 60, 2949-2954
5. Kunzmann, V.; Bauer, E.; Wilhelm, M. Gamma/delta T-cell stimulation by pamidronate N. Engl. J. Med. 1999, 340, 737-738
6. Tsagozis, P.; Eriksson, F.; Pisa, P. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages Cancer Immunol. Immunother. 2008, 57, 1451-1459
7. Rodriguez, N.; Bailey, B. N.; Martin, M. B.; Oldfield, E.; Urbina, J. A.; Docampo, R. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate J. Infect. Dis. 2002, 186, 138-140
8. No, J. H.; de Macedo Dossin, F.; Zhang, Y.; Liu, Y. L.; Zhu, W.; Feng, X.; Yoo, J. A.; Lee, E.; Wang, K.; Hui, R.; Freitas-Junior, L. H.; Oldfield, E. Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 4058-4063
9. Oldfield, E. Targeting isoprenoid biosynthesis for drug discovery: bench to bedside Acc. Chem. Res. 2010, 43, 1216-1226
10. Oldfield, E.; Lin, F. Y. Terpene biosynthesis: modularity rules Angew. Chem., Int. Ed. 2012, 51, 1124-1137
11. Liu, C. I.; Liu, G. Y.; Song, Y.; Yin, F.; Hensler, M. E.; Jeng, W. Y.; Nizet, V.; Wang, A. H.; Oldfield, E. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence Science 2008, 319, 1391-1394
12. Swiezewska, E.; Danikiewicz, W. Polyisoprenoids: structure, biosynthesis and function Prog. Lipid Res. 2005, 44, 235-258
13. Jahnke, W.; Rondeau, J. M.; Cotesta, S.; Marzinzik, A.; Pelle, X.; Geiser, M.; Strauss, A.; Gotte, M.; Bitsch, F.; Hemmig, R.; Henry, C.; Lehmann, S.; Glickman, J. F.; Roddy, T. P.; Stout, S. J.; Green, J. R. Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery Nat. Chem. Biol. 2010, 6, 660-666
14. Amstutz, R.; Bold, G.; Cotesta, S.; Jahnke, W.; Marzinzik, A.; Mueller-Hartwieg, C.; Ofner, S.; Stauffer, F.; Zimmermann, J. Quinolines as inhibitors of farnesyl pyrophosphate synthase. U.S. Patent Application PCT/EP2009/052314, September 3, 2009.
15. Ebetino, F. H.; Roze, C. N.; McKenna, C. E.; Barnett, B. L.; Dunford, J. E.; Russell, R. G. G.; Mieling, G. E.; Rogers, M. J. Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase J. Org. Chem. 2005, 690, 2679-2687
16. Martin, M. B.; Grimley, J. S.; Lewis, J. C.; Heath, H. T., 3rd; Bailey, B. N.; Kendrick, H.; Yardley, V.; Caldera, A.; Lira, R.; Urbina, J. A.; Moreno, S. N.; Docampo, R.; Croft, S. L.; Oldfield, E. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy J. Med. Chem. 2001, 44, 909-916
17. Poulter, C. D.; Satterwhite, D. M. Mechanism of the prenyl-transfer reaction. Studies with (E)- and (Z)-3-trifluoromethyl-2-buten-1-yl pyrophosphate Biochemistry 1977, 16, 5470-5478
18. Aaron, J. A.; Christianson, D. W. Trinuclear metal clusters in catalysis by terpenoid synthases Pure Appl. Chem. 2010, 82, 1585-1597
19. Liu, Y. L.; Lindert, S.; Zhu, W.; Wang, K.; McCammon, J. A.; Oldfield, E. Taxodione and arenarone inhibit farnesyl diphosphate synthase by binding to the isopentenyl diphosphate site Proc. Natl. Acad. Sci. U.S.A. 2014, 111, E2530-E2539
20. Lindert, S.; Zhu, W.; Liu, Y. L.; Pang, R.; Oldfield, E.; McCammon, J. A. Farnesyl diphosphate synthase inhibitors from in silico screening Chem. Biol. Drug Des. 2013, 81, 742-748
21. Xia, Y.; Liu, Y. L.; Xie, Y.; Zhu, W.; Guerra, F.; Shen, S.; Yeddula, N.; Fischer, W.; Low, W.; Zhou, X.; Zhang, H. Y.; Oldfield, E.; Verma, I. M. A combination therapy for KRAS-driven lung adenocarcinomas using liphophilic bisphosphonates and rapamycin Sci. Transl. Med. 2014, 6, 263ra161
22. Tarshis, L. C.; Yan, M.; Poulter, C. D.; Sacchettini, J. C. Crystal structure of recombinant farnesyl diphosphate synthase at 2.6-A resolution Biochemistry 1994, 33, 10871-10877
23. Hosfield, D. J.; Zhang, Y.; Dougan, D. R.; Broun, A.; Tari, L. W.; Swanson, R. V.; Finn, J. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis J. Biol. Chem. 2004, 279, 8526-8529
24. Rondeau, J. M.; Bitsch, F.; Bourgier, E.; Geiser, M.; Hemmig, R.; Kroemer, M.; Lehmann, S.; Ramage, P.; Rieffel, S.; Strauss, A.; Green, J. R.; Jahnke, W. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs ChemMedChem 2006, 1, 267-273
25. Kavanagh, K. L.; Guo, K.; Dunford, J. E.; Wu, X.; Knapp, S.; Ebetino, F. H.; Rogers, M. J.; Russell, R. G.; Oppermann, U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 7829-7834
26. Molecular Operating Environment (MOE), 2013.08; Chemical Computing Group Inc.: Montreal, Canada, 2014.
27. Dunford, J. E.; Thompson, K.; Coxon, F. P.; Luckman, S. P.; Hahn, F. M.; Poulter, C. D.; Ebetino, F. H.; Rogers, M. J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J. Pharmacol. Exp. Ther. 2001, 296, 235-242